GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Eric Stier sold 2,558 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.03, for a total value of $15,424.74. Following the completion of the sale, the senior vice president now owns 233,291 shares of the company’s stock, valued at approximately $1,406,744.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Eric Stier also recently made the following trade(s):

  • On Tuesday, August 20th, Eric Stier sold 1,703 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.25, for a total value of $10,643.75.

Shares of NASDAQ GNMK traded up $0.11 during trading hours on Friday, reaching $6.01. The stock had a trading volume of 164,860 shares, compared to its average volume of 243,190. The company has a quick ratio of 2.83, a current ratio of 3.39 and a debt-to-equity ratio of 3.69. The business’s fifty day moving average price is $6.25 and its two-hundred day moving average price is $6.82. GenMark Diagnostics, Inc has a 52-week low of $3.58 and a 52-week high of $8.37.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Monday, August 5th. The medical equipment provider reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). The business had revenue of $18.37 million during the quarter, compared to the consensus estimate of $17.92 million. GenMark Diagnostics had a negative return on equity of 167.54% and a negative net margin of 63.86%. Sell-side analysts expect that GenMark Diagnostics, Inc will post -0.8 earnings per share for the current year.

A number of analysts recently issued reports on the company. Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, June 13th. BidaskClub lowered GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 23rd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $10.00 price target on shares of GenMark Diagnostics in a report on Monday, July 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $9.67.

Large investors have recently modified their holdings of the stock. Bank of Montreal Can raised its stake in GenMark Diagnostics by 145.4% in the second quarter. Bank of Montreal Can now owns 7,687 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 4,554 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in GenMark Diagnostics by 56,694.7% in the first quarter. BNP Paribas Arbitrage SA now owns 10,791 shares of the medical equipment provider’s stock worth $77,000 after buying an additional 10,772 shares in the last quarter. SG Americas Securities LLC bought a new position in GenMark Diagnostics in the second quarter worth approximately $79,000. Susquehanna International Group LLP bought a new position in GenMark Diagnostics in the second quarter worth approximately $131,000. Finally, Prudential Financial Inc. bought a new position in GenMark Diagnostics in the second quarter worth approximately $141,000. 89.91% of the stock is owned by institutional investors.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: What does a market perform rating mean?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.